CTOs on the Move

Sangamo

www.sangamo.com

 
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients` lives using the company`s industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company is conducting Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington`s disease. In addition, ...
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.sangamo.com
  • 7000 Marina Boulevard
    Richmond, CA USA 94005
  • Phone: 628.252.7500

Executives

Name Title Contact Details
Michael Holmes
Senior Vice President and Chief Technology Officer Profile

Similar Companies

Comfort Safety Products

Comfort Safety Products is a Lowell, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pivotal Therapeutics

Pivotal Therapeutics is a publicly traded (OTCQX:PVTTF; CSE:PVO), specialty pharmaceutical company with a focus on cardiovascular disease and overall health. Pivotal Therapeutics` lead product VASCAZEN is a prescription only medical food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to levels associated with reduced risk of cardiovascular complications. OMAZEN is a pharmaceutical grade Omega-3 providing over 90% pure Omega-3 in each capsule for the maintenance of good health. OMAZEN® is a patented product available for sale and distribution in Canada.

Relypsa

Relypsa is a biopharmaceutical company leading the discovery, development and commercialization of polymer-based medicines to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patient lives or even be life-threatening. Relypsa was founded in October 2007 and is headquartered in Redwood City, Calif. In 2015, we received FDA approval for our first medicine, which was developed based on our polymer technology platform for the treatment of hyperkalemia. In September 2016, Relypsa became a Vifor Pharma company. Today, we have more than 400 employees united by a passion for improving people’s lives.

Kinnos

Our patented and award-winning Highlight® technology makes it easy to use disinfectants correctly.

BioNJ

BioNJ is a Trenton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.